Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

23 Oct 2017

Abstract excerpt

Abstract NAMPT, an enzyme essential for NAD+ biosynthesis, has been extensively studied as an anticancer target for developing potential novel therapeutics. Several NAMPT inhibitors have been discovered, some of which have been subjected to clinical investigations. Yet, the on-target hematological and retinal toxicities have hampered their clinical development. In this study, we report the discovery of a unique...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Calcium signaling and nucleotide metabolism
Share to Sirtuins and Resveratrol in Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29054982
DOI: 10.1158/1535-7163.mct-16-0674

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid CoadministrationPMID 29054982Read ↗

Mechanisms of resistance to NAMPT inhibitors in cancerSemantic proximity Read ↗

Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA RepairSemantic proximity Read ↗

Advances in NAD-Lowering Agents for Cancer TreatmentSemantic proximity Read ↗

Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide PhosphoribosyltransferaseSemantic proximity Read ↗

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.Semantic proximity Read ↗

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug DiscoverySemantic proximity Read ↗

Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.Semantic proximity Read ↗

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT InhibitorsSemantic proximity Read ↗

Structural basis for resistance to diverse classes of NAMPT inhibitors.Semantic proximity Read ↗

Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancerSemantic proximity Read ↗

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD <sup>+</sup> Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient TumorsSemantic proximity Read ↗

Updated Functional Roles of NAMPT in Carcinogenesis and Therapeutic NichesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.